ArticleIndian journal of pharmacology2026
A rare intravenous paraquat exposure presenting with novel and atypical severe clinical manifestations.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractParaquat is a highly toxic bipyridyl herbicide that continues to be used in several countries despite restrictions elsewhere. While ingestion is the most common route of poisoning, intravenous administration is rare and associated with extremely high mortality. We report the case of a 26-year-old male who attempted suicide by self-injecting 10 mL of 24% paraquat dichloride intravenously into the dorsal metacarpal region. Within hours, he developed hematemesis, diaphoresis, giddiness, chills, agitation, and diffuse burning sensations. On admission, he was alert but drowsy with bradycardia, pedal edema, and local swelling at the injection site. Laboratory findings revealed leukocytosis, elevated serum creatinine, hypokalemia, and metabolic acidosis. Despite early hemodialysis, continuous renal replacement therapy, and administration of antioxidants and supportive treatment, the patient developed progressive respiratory distress, refractory hypotension, and recurrent cardiac arrests. He died 28 h after admission. Intravenous paraquat poisoning is rare but uniformly fatal. This case emphasizes the importance of early recognition, aggressive supportive care, and the continued need for preventive strategies and regulatory measures to limit paraquat availability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.